China Resources Sanjiu Medical & Pharmaceutical Co (000999) Q2 2026 earnings summary

Executive summary

• Achieved revenue of ¥15.01 billion, up 1.37% year-over-year; net profit attributable to shareholders was ¥1.67 billion, down 7.96% year-over-year.

• Focused on innovation and brand-driven strategy, strengthening R&D and optimizing business structure.

• Maintained industry leadership in OTC and prescription drug segments, with strong performance in core therapeutic areas.

Financial highlights

• Operating income: ¥15.01 billion, up 1.37% year-over-year.

• Net profit attributable to shareholders: ¥1.67 billion, down 7.96% year-over-year.

• Basic and diluted EPS: ¥1.00, down 8.26% year-over-year.

• Operating cash flow: ¥2.42 billion, down 15.29% year-over-year.

• Gross margin for CHC: 61.25%; prescription drugs: 64.62%.

Outlook and guidance

• Industry faces short-term pressure from regulatory and market changes, but long-term growth remains robust due to aging population and policy support.

• Continued focus on R&D, product innovation, and digital transformation to drive future growth.